Today, within the R&D pipelines of pharmaceutical companies, monoclonal antibodies are gradually being replaced by new-generation biotherapeutics, including engineered hybrid and multispecific constructs. While these innovative formats hold great therapeutic promise, their structural complexity often leads to unexpected in vivo instabilities that may compromise efficacy or alter...
Antibodies show tremendous structural diversity shaping their biological functions in immunity and immune pathologies. While IgG1 Fc domains have been extensively characterized by MS approaches, more complex antibody structures (including Fab glycosylated IgGs or isotypes such as IgA or IgM) are less well understood. This presentation showcases the integration of miniaturized bottom-up,...
Mass spectrometry (MS) is essential for characterizing biotherapeutics, with Top-Down (TD) and Middle-Down (MD) approaches offering faster alternatives to peptide mapping. Despite achieving high sequence coverage using advanced fragmentation techniques like HCD, ETD, and UVPD, traditional data analysis presents challenges. These include time-consuming fragmentation map creation, difficulty...
The Twister algorithm (Vyatkina et al., 2015, 2016, 2017), initially intended for de novo sequencing of antibodies from top-down MS/MS data supported with high-resolution bottom-up MS/MS spectra, is being developed further – currently aiming, at particular, at taking the maximum profit from internal fragment ions. In this talk, we will present the latest version of the Twister algorithm,...
Immunoassays for cardiac troponin, such as the Elecsys® hs-TnT, have become the gold standard for myocardial infarction diagnostics. While various protein/chemical factors affecting the troponin complex and, thus, its diagnostic accuracy have been investigated the role of coding single nucleotide polymorphisms remains underexplored. To evaluate potential cSNP-induced interference with antibody...
